Search

Your search keyword '"Kallieri, Maria"' showing total 114 results

Search Constraints

Start Over You searched for: Author "Kallieri, Maria" Remove constraint Author: "Kallieri, Maria"
114 results on '"Kallieri, Maria"'

Search Results

1. SARS-Cov-2 Infection in Severe Asthma Patients Treated With Biologics

2. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

3. Effects of menopause and fat mass in asthmatic inflammation.

4. Sensitization to Staphylococcus Enterotoxin: Relationship with Aspects of Disease Severity.

5. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study

7. Switching from omalizumab to mepolizumab in severe asthmatics: A post hoc analysis of the RELight study.

8. Patients Hospitalized for COVID-19 in the Periods of Delta and Omicron Variant Dominance in Greece: Determinants of Severity and Mortality

9. Autoimmune Pulmonary Alveolar Proteinosis (aPAP) in Greece: 20 years in progress

10. Comparison of patients hospitalized for COVID-19 in the periods of Delta and Omicron variants dominance in Greece

11. The clinical experience of patients with severe asthma and previous treatment with omalizumab, choosing mepolizumab in Greece.

12. Diffuse panniculitis in a teen male with ZZ alpha1-antitrypsin deficiency

13. Φαινοτυπικός καθορισμός ασθενών με άσθμα και χρόνια αποφρακτική πνευμονοπάθεια

14. Genetics in Idiopathic Pulmonary Fibrosis: A Clinical Perspective

16. Sestrin 2 levels are associated with emphysematous phenotype of COPD

17. COVID-19 in patients with pulmonary alveolar proteinosis: a European multicentre study

18. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

19. Real World Biologic Use and Switch Patterns in Severe Asthma:Data from the International Severe Asthma Registry and the US CHRONICLE Study

20. Epidemiological characteristics, clinical features and outcomes of patients with COVID-19 admitted to seven reference centers across Greece: An observational study during the fourth and fifth waves of the COVID-19 pandemic.

21. RELIght: A two‐year REal‐LIfe study of mepolizumab in patients with severe eosinophilic asTHma in Greece: Evaluating the multiple components of response

22. Autoimmune PAP (aPAP) in children

23. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

24. Pulmonary hemorrhage in patients receiving anti-platelets- a case series and a suggested therapeutic algorithm

25. Real World Biologic Use and Switch Patterns in Severe Asthma: Data from the International Severe Asthma Registry and the US CHRONICLE Study

26. COVID-19: the day after

27. COVID-19: the day after

28. Device use errors among patients with asthma and COPD and the role of training: a real-life study

29. Global Variability in Administrative Approval Prescription Criteria for Biologic Therapy in Severe Asthma

30. Device use errors among patients with asthma and COPD and the role of training: a real-life study

31. Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

32. Genotyping and phenotyping of alpha1-antitrypsin deficiency Greek patients under augmentation therapy: a multicenter study

33. Follow-up of patients with severe eosinophilic asthma receiving mepolizumab for one year in specialized asthma clinics in Greece

34. Devise use errors among patients with asthma and COPD-A real-life study

35. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study

36. Mepolizumab in Severe Eosinophilic Asthma: A 2-Year Follow-Up in Specialized Asthma Clinics in Greece: An Interim Analysis

38. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients

39. Lung disease caused by non-null ABCA3 mutations: long-term follow-up

41. Mycophenolate mofetil as an alternative treatment in sarcoidosis

42. Kartagener’s syndrome: A multisystem disease in need of a “multidisciplinary approach” concept.

43. Skipping a single dose of mepolizumab resulted in significant clinical and functional deterioration.

44. Prevalence, distribution and clinical significance of joints, muscles and bones in sarcoidosis: an 18F-FDG-PET/CT study.

45. Lung disease caused by non-null ABCA3 mutations: long-term follow-up

46. TERT/TERC mutations in a Greek cohort of suspected genetic pulmonary fibrosis patients

47. The effects of pulmonary rehabilitation in patients with Combined Pulmonary Fibrosis and Emphysema (CPFE)

48. Mycophenalate Mofetil as a corticosteroid- sparing agent in patients with sarcoidosis.

Catalog

Books, media, physical & digital resources